Business Context and Reporting Period
Calidi Biotherapeutics, Inc. (CLDI), a Delaware corporation and emerging growth company, filed this Form 8-K on June 3, 2024, to report the closing of a warrant inducement transaction. The company is based in San Diego, California, and its securities trade on the NYSE American LLC.
Key Financial Metrics and Transaction Details
This filing details a capital raise mechanism rather than standard operating financial results. Key transaction metrics include:
- Transaction Type: Inducement offer letter agreement for the immediate exercise of existing Series B and Series C warrants.
- New Securities Issued: Up to 10,698,000 New Series D common stock purchase warrants.
- Exercise Price (New Warrants): $0.30 per share.
- Term (New Warrants): 66 months from issuance.
- Placement Agent Warrants (PA Warrants): 534,900 warrants issued to Ladenburg Thalmann & Co, Inc. (5.0% of underlying shares).
- PA Warrant Terms: Exercise price of $0.375 per share; 5-year term.
- Use of Proceeds: Advancing clinical and pre-clinical programs, continuing operating expenses, and working capital.
The filing text does not provide a clear value for the aggregate gross proceeds received from the exercise of the Existing Warrants, though fees were calculated as a percentage of this amount.
Material Changes and Agreements
The primary material change is the entry into a definitive agreement with 9 holders of existing warrants. In exchange for the immediate cash exercise of their existing warrants, the Company agreed to issue the new Series D warrants. Additionally, the Company engaged Ladenburg Thalmann & Co, Inc. as the exclusive financial advisor, agreeing to pay:
- A fee equal to 8.0% of aggregate gross proceeds.
- A management fee of 1.0% of aggregate gross proceeds.
- Reimbursement for accountable legal expenses.
- The issuance of the PA Warrants described above.
Outlook, Risks, and Contingencies
Management intends to utilize the net proceeds to advance clinical and pre-clinical programs. The New Series D Warrants are initially exercisable only upon receipt of required stockholder approvals under NYSE American rules. The PA Warrants were issued pursuant to Section 4(a)(2) and Regulation D exemptions and are unregistered; they may not be offered or sold in the United States absent registration or an applicable exemption.
Investor Verification Checklist
- Verify the total aggregate gross proceeds generated from the exercise of the Existing Warrants to calculate the exact fees paid to the placement agent.
- Confirm the status of the required stockholder approvals for the New Series D Warrants to become exercisable.
- Review the specific terms of the Inducement Letter and New Series D Warrants filed as Exhibits 10.1 and 4.1 in the May 31, 2024, and June 3, 2024, filings.
- Assess the dilution impact of the 10,698,000 new warrants and 534,900 PA Warrants on existing shareholders.